Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) reported Q3 EPS of $0.00, $0.10 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $420 thousand versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Aridis Pharmaceuticals, Inc. (ARDS) click here.